Silenor’s Bleary Regulatory Timeline May Clear Up
This article was originally published in The Pink Sheet Daily
Executive Summary
Somaxon’s sleep aid is on track for a third-quarter NDA submission; partnering deal also expected during 2007.
You may also be interested in...
Somaxon To Put Silenor Phase III Program To Bed In December
Firm's Q3 2007 filing timeframe puts it ahead of Neurocrine's resubmission plans for immediate-release indiplon.
Neurocrine Delays Indiplon Resubmission To Run Confirmatory Trial
Adding an insurance study to the NDA package means Neurocrine could finally see income from the insomnia aid in late 2008.
Somaxon To Conduct Preclinical Tests On Its Phase III Insomnia Drug Silenor
FDA has requested that preclinical studies on low-dose doxepin be included in the 505(b)(2) application.